Sagimet Biosciences Inc. (SGMT) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -52.63M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 34.99M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-52.63M | (m) | (m) | $34.99M | (m) | (m) |
| 2026-03-31 | $-48.74M | (m) | (m) | $30.71M | (m) | (m) |
| 2025-12-31 | $-56.89M | (m) | (m) | $39.05M | (m) | (m) |
| 2025-09-30 | $-64.32M | (m) | (m) | $46.54M | (m) | (m) |
| 2025-06-30 | $-66.89M | (m) | (m) | $49.46M | (m) | (m) |
| 2025-03-31 | $-65.55M | (m) | (m) | $48.52M | (m) | (m) |
| 2024-12-31 | $-54.45M | (m) | (m) | $38.44M | (m) | (m) |
| 2024-09-30 | $-45.73M | (m) | (m) | $29.88M | (m) | (m) |
| 2024-06-30 | $-36.27M | (m) | (m) | $22.19M | (m) | (m) |
| 2024-03-31 | $-32.74M | (m) | (m) | $20.55M | (m) | (m) |
| 2023-12-31 | $-30.74M | $2.00M | (m) | $19.78M | (m) | -1537.00% |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-31.05M | (m) | (m) | $24.92M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |